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ABSTRACT: The Mucopolysaccharidoses (MPS) are lysosomal storage disorders that result from defects in the catabolism of
glycosaminoglycans. Impaired muscle, bone and connective tissue are typical clinical features of MPS due to disruption of the ex-
tracellular matrix. Markers of MPS disease pathology are needed to determine disease severity and monitor effects of existing and
emerging new treatments on disease mechanisms. Urine samples from a small cohort of MPS-I, II and VI patients (n=12) were ana-
lysed using label-free quantative proteomics. Fifty three proteins including many associated with extracellular matrix organisation
were differently expressed, A targeted multiplexed peptide MRM LC-MS/MS assay was used on a larger validation cohort of pa-
tient samples (MPS-I n= 10, MPS-II n= 15, MPS-VI n= 5, Control n=20). MPS-I and-II groups were further sub-divided according
to disease severity. None of the markers assessed were altered significantly in the mild disease groups compared to controls. Beta-
galactosidase, a lysosomal protein, was elevated 3.6-5.7-fold significantly (p<0.05) in all disease groups apart from mild MPS-I and
II. Collagen type I, fatty-acid-binding-protein 5, nidogen-1, cartilage oligomeric matrix protein and insulin-like growth factor
binding protein 7 concentrations were elevated in severe MPS I and II groups. Cartilage oligomeric matrix protein, insulin-like
growth factor binding protein 7 and beta-galactosidase were able to distinguish the severe neurological form of MPS-II from the
milder non-neurological form. Protein Heg1 was significantly raised only in MPS-VI. This work describes the discovery of new
biomarkers of MPS that represent disease pathology and allows the stratification of MPS-II patients according to disease severity.
Mucopolysaccharidoses (MPS) are part of a larger group of
rare genetic metabolic disorders known as Lysosomal Storage
Diseases (LSDs), incidence of the various forms of MPS range
from 0.05-1.89/100,000 live births 1. MPS results from a de-
fect in enzymes involved in the glycosaminoglycan (GAG)
degradation pathway, resulting in the lysosomal accumulation
of GAGs, which results in progressive cellular damage, multi-
ple organ failure and reduced life expectancy2. To date the
MPS disorders have been classified into seven distinct forms,
which relate to the enzyme affected in the GAG degradation
pathway; each MPS disease results in elevation of various
GAG species of heparan, dermatan, keratan, chondroitin sul-
phates and hyaluronan. Pathological features of MPS typically
include skeletal and connective tissue abnormalities with pa-
tients often presenting with skeletal dysplasia, decreased joint
mobility, short stature and carpal tunnel syndrome. MPS dis-
orders have a wide variation in disease phenotype, with mild
forms that manifest in adulthood and severe forms that are
apparent in infancy1. MPS I is further subdivided into Hurler
disease, which has a severe clinical phenotype, Scheie disease,
which is a clinically milder form of MPS I, and Hurler-Scheie,
which has common characteristics of both phenotypes. MPS II
is typically the severe neurological form of the disease whilst a
non-neurological form is considered the milder variant. Avail-
able therapy for MPS disorders include hematopoietic stem
cell transplantation and enzyme replacement therapy (ERT)
for MPS I, II and VI3. To maximise the success of treatment it
is necessary to diagnose these patients as early as possible.
Currently, there is no simple and rapid test for the diagnosis of
MPS. Suspected patients are tested for the presence of accu-
mulated urinary GAGs which are typically performed using
semi-quantitative electrophoresis techniques4. Quantitation of
disaccharides of GAGs using tandem LC-MS methods are
being developed 5,6 and assessed for routine clinical practice.
Whilst an observed reduction of the respective GAG species is
used to monitor treatment of MPS patients, it
Table 1: Cohort sample information for disease phenotype, age and sex. All samples were reported GAG positive by the
Great Ormond street diagnostic Enzyme laboratory.
Biomar ker
Discovery Cohor t
Control MPS I MPS II MPS VI
number 10 4 5 2
Age range (years) 2-39 1-9 4-9 5 & 7
Sex ratio
Male:Female 5:5 2:2 5:0 1:1
Validation Cohor t PaediatricControl
Adult
Control
MPS I
(Hurler-Hurler-
Scheie)
MPS I
(mild)
MPS II
(Neurological form)
MPS II
(non-neurological
form)
MPS VI
number 9 10 14 4 5 7 6
Age range (years) 2.5-11 21-39 1.5-14 12-34 1-5 1-12 0.24 -17
Sex ratio
Male:Female 5:5 5:5 4:8 3:1 4:1 7:0 3:3
provides limited information on improvement in the pathology
of the disease and hence GAGs are not considered ideal bi-
omarkers for this7. Furthermore, no established biomarkers are
available to monitor the course of neurological disease. Alt-
hough the pathogenesis of MPS is due to progressive storage
of GAGS, it is becoming apparent for many lysosomal storage
disorders that more complex pathogenic mechanisms underlie
patients' clinical symptoms. Therefore there is a need for bi-
omarkers for MPS disorders to accompany GAG analysis.
Ideal markers would be specific to a particular type or types of
MPS, help to differentiate more severe from less severe dis-
ease phenotypes, correlate with neurological progression, re-
spond to treatment and be easily detected and quantified.
Three forms of MPS were used in this study. MPS I patients
(Hurler, Hurler-Scheie, Scheie syndrome) who have defects in
alpha-L-iduronidase, MPS II patients (Hunter syndrome) who
have defects in iduronate sulfatase of which both are involved
in the catabolism of heparan and dermatan sulphate, and MPS
VI (Maroteaux–Lamy syndrome) patients who lack arylsulfa-
tase B activity, involved in the catabolism of dermatan sul-
phate. This study has been performed to identify potential
MPS biomarker candidates in patient urine using label free
proteomics to compare initially a small cohort of urine sam-
ples from GAG positive MPS I, MPS II and MPS VI patients.
Potential marker candidates were further developed into a
targeted proteomic MRM LC-MS/MS assay to confirm the
findings on a larger sample cohort.
Experimental Section
Ethics Approval: The study was performed under ethical
approval given by the NHS Research Ethics committee Lon-
don-Bloomsbury.
Sample collection: Samples were obtained from patients at-
tending the metabolic clinic at Great Ormond Street Hospital,
London and from adult patients attending a clinic at the Na-
tional Hospital, Queen Square, London. Samples were clini-
cally requested for urinary GAGs analysis and appropriate
metabolic investigations as part of clinical care. Excess sam-
ples were selected that had tested positive for both elevated
urine GAGs and reduced enzymatic activity; surplus urine
samples were stored at -80oC. Patient disease diagnosis (con-
sidered mild or severe) age, sex and GAG status were provid-
ed for anonymised samples. Sex and age details are summa-
rized in table 1.
Label Free Proteomics: Label free proteomics was performed
as described previously8. Urine samples were thawed, centri-
fuged to remove particulate and cell debris and 5 mls filtered
using a 3 kDa molecular weight cut off filter (Millipore, UK).
Desalted urine was protein assayed using the BCA protein
assay kit (Sigma UK). 100 g of protein was freeze dried,
trypsin digested, yeast enolase peptide internal standard (Wa-
ters Corp. Milford, MA)was added to digests to a final concen-
tration of 100 fmol/l and the digests desalted prior to analysis
using C18 spin columns (Agilent, UK). Digested peptides
were re-suspended in 3% ACN, 0.1% TFA and analysed on a
Waters QToF Premier mass spectrometer coupled to a
NanoAquity UPLC. Each digest was analysed using a 1.5 hour
LC-MSe analyses as described previously in our laboratory9.
Proteins were identified using Waters ProteinLynx Global
server v 3.0 with a downloaded UniProt human reference pro-
teome database to which the sequence of P00924 yeast enolase
and P00761 porcine trypsin were added manually. Fixed mod-
ifications of carboamidomethylation of cysteines, dynamic
modifications of deamidation of asparagine/glutamine and
oxidation of methionine, up to 3 missed cleavage sites and
false discovery rate set at 4% mass tolerance for ion and frag-
ments were set to auto. Only protein identifications with >95%
confidence and more than 1 peptide were exported for differ-
ential expression analysis using Progenesis LC-MS software
(non-linear dynamics, UK). ANOVA was used to determine
significance in protein expression between groups for the label
free proteomics discovery analysis. Whilst sample numbers for
discovery were small, robust potentially useful markers would
ideally show obvious changes that can then be confirmed by
targeted analysis.
Table 2. MRM parameters for the quantotypic tryptic peptides for the 7 confirmed urine marker proteins. Product ions in
bold are the optimal transitions.
Uniprot
accession Description Peptide sequence
Precursor
ion m/z
product
ion m/z
Cone
energy
Collision
energy Fragmention
Q01469 Fatty acid-binding protein, epidermal FEETTADGR 513.462+ 620.47 52 14 y6
749.63 52 16 y7
P49747 Cartilage oligomeric matrix protein LVPNPGQEDADR 656.052+ 550.00 46 16 y10
887.69 46 22 y8
P14543 Nidogen 1 EDLSPSITQR 573.352+ 351.4 29 26 y62+
701.60 29 16 y6
Q99715 Collagen alpha 1 XII chain ITWAPFGSSDK 605.092+ 498.00 26 14 y92+
737.61 26 16 y7
P16278 Beta-galactosidase AYVAVDGIPQGVLER 794.162+ 334.29 36 32 b3
1083.94 36 26 y10
Q9ULI3 Protein HEG homolog 1 ALSLAPLAGAGLELQLER 608.343+ 684.31 22 16 y132+
819.97 22 10 y162+
Q16270 Insulin like growth factor binding
protein 7
TELLPGDR 451.072+ 344.3 52 16 B3
670.65 52 16 y6
P00924 Internal standard- Enolase 1
Saccharomyces cerevisiae
SIVPSGASTGVHEALEMR 614.573+ 771.72 46 14 y152+
AVDDFLISLDGTANK 790.152+ 661.48 46 16 b6
GNPTVEVELTTEK 709.052+ 623.4916 46 18 y112+
Targeted MRM LC-MS/MS Assay: Candidate markers were
selected based on significance, fold change (>2 fold) and qual-
ity of the label free proteomics analysis data (i.e. the most
number of quantitating peptides). Additional and potential
biomarkers from the lysosomal GAG catabolic pathway were
also included in the final multiplexed assay to see if they could
be detected by targeted analysis. Two representative quanto-
typic peptides for each protein were determined from the label
free proteomics data (top 3 most abundant and optimum
daughter spectra for quantitation). Other peptides were select-
ed using the open source online Global Proteome Machine
MRM database at www.gpm.org10. Custom synthesised pep-
tides (Genscript, USA) were used to optimise the peptide de-
tection, determine retention times and identify unequivocally
the correct peptide/s in urine. The optimal peptide from the
selection of 2 peptides/protein and two transitions was chosen
based on levels of detection in urine and reflection of quantita-
tive values. Details of confirmed marker peptides are given in
table 2. Transitions were also assessed and selected for non-
interfering peaks as determined by a standard curve. Con-
firmed peptide chromatograms and standard curves are given
in supplementary data figure S1. Stable isotope peptide inter-
nal standards cannot be used in this sample work up as they
are lost during the filtration/purification step. Intact heavy
labelled proteins would act as ideal standards for this work-
flow however they are not practical for a potential high
throughput assay at this stage due to the low yield, cost and
complexity of their synthesis. Twenty nanograms of a generic
yeast enolase whole protein standard (Sigma,
Figure 1. A. Summary Venn diagram of the label free proteomics analysis indicating the number of shared and unique proteins altered in
MPS I, II and VI compared with controls. B Summarised illustration of the MPS disease pathology related pathways as identified by Reac-
tome pathway over-representation analysis. Many pathways listed in supplementary data table S-2 are part of extracellular matrix organiza-
tion.
UK) was used as an internal standard which can control for
filtration and trypsin digestion. Yeast enolase is typically used
in label free proteomics therefore is an established protein
used for standardization and quantitation. This was added to
1ml of urine before sample processing and prepared as de-
scribed previously for label free proteomics analysis. Digested
peptides were injected onto a Waters CORTECS UPLC C18 +
Column, 90Å, 1.6 µm, 3 mm X 100 mm column attached to a
C18+ VanGuard Pre-column. UPLC and MS tune conditions
were performed as described previously8. Dynamic multiple
reaction monitoring was performed over a 10 min gradient
with a minimum of 0.01 sec dwell time for quantitative transi-
tions and minimum 12 data points per peak on a Waters Xevo
TQ-S Mass Spectrometer. Urine creatinine was measured by
LC-MS as described previously11. Quality Controls (QC)
made of pooled urine digests were run in triplicate at the start
of the run and then every 10 injections. A CV of + /- 15% for
each QC was considered acceptable. Samples were run in du-
plicate. Urine was spiked with peptides to create standards
with average concentrations of biomarker levels and analysed
for intra- and inter-batch variation. Chromatograms were ana-
lysed using Waters TargetLynx software. Peptides were stand-
ardised by using a yeast enolase peptide. Absolute levels were
obtained from standard curves and standardised to urinary
creatinine. Data was exported to Microsoft Excel and
GraphPad Prism for statistical analysis. Analyses included
data QC for peptide performance (coefficient of variance), QC
of sample preparation and LC-MS/MS performance (yeast
enolase). Standard curves were analysed by linear regression
analysis and Pearson’s correlation. Expression of candidate
marker levels were checked for the effect of age by linear re-
gression (Supplementary data, FigureS2) and non-parametric
t-test (Mann Witney test). Where no age effect was observed
the two control groups were grouped as one in the analysis.
Where an age-specific correlation was observed then compari-
son with disease groups was only with the corresponding con-
trol age group. Group comparisons were performed using the
non-parametric Mann Whitney test.
RESULTS
Label free proteomics: Fifty three significantly differentially
expressed proteins were observed in the urine of the MPS dis-
ease patients compared to controls (p<0.05) and are listed in
supplementary data table S-1. Figure 1 provides a summary of
the analysis. Seventeen proteins were common to all disorders.
More proteins were common to MPS I and II than with MPS
VI. This is likely due to the similarity of these two MPS disor-
ders which affect the same degradation pathway for heparan
and dermatan sulphate whilst MPS VI only affects the derma-
tan sulphate pathway. Significant differentially expressed pro-
teins were subjected to gene ontology analysis. Over-
represented pathway analysis was performed using the curated
pathway database Reactome 12,13. Significantly affected path-
ways indicated from the proteins detected in MPS urine are
listed in supplementary data table S-2 and summarized in fig-
ure 1B. The most significant pathway affected is extracellular
matrix (ECM) organisation. Many other highlighted pathways
are implicated in other ECM related functions in particular the
ECM involvement with wound healing.
Targeted MRM LC-MS/MS analysis: A multiplex and tar-
geted proteomic assay using 1ml of urine was developed to
confirm the findings from the label free proteomics. Proteins
selected for confirmation are indicated in supplementary data
table S-1. Additional proteins included in the assay were en-
zymes involved in the GAG degradation pathway that were
not detectable with our current limits of detection in the QTOF
discovery analysis but may be detectable by more sensitive
targeted analysis in the experiments. Of these additional pro-
teins only beta galactosidase was significantly altered in the
study. Other additional proteins were either not detectable or
not significant. A total of 52 peptide transitions were included
in the assay. Twenty five were reliably quantifiable in 1ml of
urine. A summarized overlaid chromatogram of the significant
markers is shown in figure 2.
Figure 2. Overlaid chromatogram of multiplexed MRM quantita-
tion including 7 MPS marker proteins in a single 10 minute LC-
MRM/MS run.
Candidate markers were analysed for effect of patient age
before comparative analysis; only collagen I (alpha chain)
concentration was significantly age-dependent. Therefore,
collagen I comparison of the disease groups was compared
with paediatric controls only. Using this targeted proteomic
approach, we were able to confirm that seven biomarkers
demonstrated statistically significantly altered protein levels in
the urine compared to controls. Six markers were elevated
significantly in the MPS I (Hurler/Hurler-Scheie) and the MPS
II groups (neurological form) groups.
Figure 3. Targeted MRM LC-MS/MS analysis results showing the mean ± SD of proteins found significantly elevated in MPS I and II
compared to controls. Adult Control n= 20, Pediatric Control n= 10 MPS I H + HS (Hurler and Hurler-Scheie) n=13, MPS I mild n=3
MPSII Neuro (neurological phenotype) n= 5, MPSII non-neurological n=8 and MPS VI n= 5. * indicates p<0.01-0.05, ** indicates
p<0.001-0.01, *** p<0.0001-0.001.
Figure 4. Targeted MRM LC-MS/MS analysis results showing the mean ± SD of proteins found significantly elevated in MPS that can
also discriminate the neurological and non-neurological MPS II phenotype. Control n= 10, MPS I n=15, MPS II n= 13 and MPS VI n= 5.
Control n= 20, MPS I H + HS (Hurler and Hurler-Scheie) n=13, MPS I mild n=3 MPS II Neuro (neurological phenotype) n= 5, MPS II
non-neurological n=8 and MPS VI n= 5. * indicates p<0.01-0.05, ** indicates p<0.001-0.01
6Those that could only distinguish the MPS I and MPS II
groups from the respective control group were 2.8 and 3.2 fold
increases in collagen I (alpha chain), 3 and 4.2 fold increases
in fatty acid binding protein 5 (FABP5) and 2.4 and 3 fold
increases in nidogen-1 (Figure 3). Slightly raised levels but
not statistically significant were observed in the mild MPS I
and II groups. Another three markers, cartilage oligomeric
matrix protein (COMP), insulin-like growth factor binding
protein 7 (IGFBP7) and beta-galactosidase were raised signifi-
cantly compared to controls but were also significantly elevat-
ed between the MPS II neurological form and the mild non-
neurological form (Figure 4). COMP demonstrated a 1.7 and
2.4 fold change in MPS I and II, and a 2.5 fold change be-
tween the two MPS II groups. IGFBP7 demonstrated similar
changes as COMP with 1.6 and 2.4 fold changes in MPS I and
II compared with controls, and a 2.1 fold change between the
MPS II groups respectively. Beta galactosidase also demon-
strated an increase in the MPS VI group with a 3.6 fold
change. A 5.7 and 5.3 fold change was observed in the MPS I
and II groups, and a 3.5 fold change observed between the two
MPS II groups. None of the markers were able to show signif-
icance between the MPS I (Hurler/Hurler-Scheie) group and
the mild form of MPS I. Protein HEG1 was the only marker
raised significantly in one specific disease group, MPS VI,
which demonstrated a 1.9 fold elevation compared to controls.
Raised levels were observed but not specific in the neurologi-
cal MPS II group (Figure 5). A summary table of the signifi-
cant marker observations is provided as supplementary data
table S-3.
Figure 5. Targeted MRM LC-MS/MS analysis results showing the
mean ± SD of the significantly elevated protein HEG1 in MPS VI.
Control n= 20, MPS I Hurler and Hurler-Scheie n=13, MPS I mild
n=3 MPS II neurological form n= 5, MPS II non-neurological n=8
and MPS VI n= 5. * indicates p<0.01-0.05.
Liner regression analysis was performed on the MPS I Hurl-
er/Hurler Scheie group to see if any of the markers showed a rela-
tionship with age progression. Only nidogen 1 showed a weak but
significant correlation (r2=0.44, p<0.019) and is shown in sup-
plementary figure data 2B. Nidogen 1 was not noticed to be af-
fected by age in the control cohort (supplementary figure 2A)
therefore this may possibly be a marker for disease progression.
Discussion
The MPS disorders are diagnosed currently using either very
labour intensive enzymatic tests or by the analysis of urinary
GAG species. Although laboratories are moving to higher
throughput LC-MS based systems for quantitative GAG anal-
ysis these are still complicated assays to develop and interpret.
Current GAG analysis cannot discriminate the different dis-
ease severity phenotypes of MPS I and II. Whether future LC-
MS disaccharide analysis will be able address this remains to
be determined. Therefore, we investigated potential surrogate
urine markers that could provide additional information to
distinguish the different disorders and their subtypes. Fur-
thermore, the identification of markers for biological systems
affected in MPS, (for which total GAG levels provide no use-
ful information) would provide data to stratify patients regard-
ing prognosis and response to therapy. Additionally, bi-
omarkers may be developed into a rapid and sensitive test for
monitoring MPS disorders. This is particularly important with
the increasing numbers of enzyme replacement therapies be-
coming available, where it would be necessary to diagnose
and stratify patients earlier and also monitor treatment re-
sponse.
Only recently have there been studies attempting to identify
further biomarkers that can be used to detect pathological
mechanisms associated with MPS. In accordance with our
data, proteomic and genome wide expression studies of the
MPS I mouse model14, reported early disruption of the extra-
cellular matrix. The biomarker discovery phase of this study
was performed on just a small cohort of MPS I, II and VI
samples as the MPS disorders are extremely rare so large co-
horts of samples are impossible to collect. However, we were
able to identify differentially expressed proteins which the
primary biological pathway implicated was extracellular ma-
trix organisation. This finding confirmed that markers of the
underlying pathological features of this disease can be detect-
ed in patient urine. Some of the proteins reported in the mouse
model were also detected in the present study (collagen type 1,
COMP, and fibronectin). ECM proteins that were able to be
confirmed , and could be used potentially to monitor ECM
integrity in MPS I and II, are COMP, nidogen 1 and collagen
type 1 (figure 3 &4). Protein HEG1 homologue (Heart of
Glass receptor 1) is an endothelial cell junction protein identi-
fied as elevated significantly in only the MPS VI disease
group. HEG1 is crucial for heart and vessel formation and
integrity15. Whilst the function of HEG1 has been investigated
largely in the heart according to the protein expression data-
base Model Organisation Protein Expression Database
(MOPED)16 HEG1 protein expression is not limited to heart
tissue. Therefore the origin of HEG1 in urine could be at-
tributed to other tissues and its relevance to MPS VI pathology
may also be indicative of impaired endothelial function which
is a known pathological feature of MPS 17. FABP5 which was
elevated significantly in the severe MPS I and II groups (fig-
ure 3b), is a known epidermal and endothelial tissue protein
found in heart and skeletal muscle but does not form part of
the ECM. It has been postulated previously as a marker for
cardio-metabolic risk factors and carotid atherosclerosis 18.
Coronary artery pathology including atherosclerosis and endo-
thelial dysfunction are a prominent feature of the MPS disor-
ders17,19. Therefore, FABP5 and protein HEG1 have the poten-
7tial to act as surrogate markers of monitoring for a patient’s
endothelial function. Beta galactosidase was elevated signifi-
cantly in all MPS disease groups (figure 4c) and was also the
most statistically significant and had the greatest fold changes.
Beta galactosidase is involved in keratan sulphate catabolism
and not heparan and dermatan sulphate catabolic pathways
which are involved in the GAG catabolic pathways affected in
MPS I, II and VI. The reason for increased levels of beta-
galactosidase in MPS I, II and VI relative to the control group
are unknown but lysosomal beta galactosidase is thought to be
a marker of senescence and previous studies have linked its
increased expression to an increase in lysosomal mass and or
number 20-22. Lysosomal hypertrophy is known to occur in
MPS disorders 23 therefore increased beta galactosidase may
potentially be a marker for increased lysosomal load.
Not all of the markers described in the discovery analyses
were confirmed in the same MPS groups. The reasons for this
may be due to differences in sample numbers between the
discovery and validation analyses using the targeted test. The
greater sample numbers and different levels of disease severity
in the larger groups may explain why there are significant yet
different observations compared with the label free analysis.
This emphasises the need to confirm initial biomarker findings
in larger cohorts, since biomarker discovery is low throughput
and confirmation of potential markers should be performed
using high throughput targeted techniques. The accumulation
of a large enough cohort of samples, due to the rarity of the
conditions, would require a large multicenter study conducted
over years, something not possible at this point.
The bottleneck and issues of translation of biomarkers into the
clinical setting is well known 24 25. Targeted proteomics, par-
ticularly SRM/MRM LC-MS/MS analysis, is gaining more
interest as it has great potential for clinical translation26,27
since most large hospitals have triple
quadrupole based platforms. Potential assays for clinical rou-
tine analysis ideally would be simple in preparation and data
handling/processing but also need to be, robust, reproducible
and cost effective. The targeted assay platform we describe
here has been designed purposely with these factors in mind,
to enable its potential further development for use in future
clinical trials using these markers. The assay only requires 1-
2mls of urine, a generic cost effective whole protein standard
is used to control for sample preparation and act as an internal
standard. The assay is also potentially cost effective compared
to other methods as it can multiplex the quantitative analysis
of many proteins in one run and the LC conditions have been
devised over a simple 10 min gradient which enables high
through-put potential of the assay.
Conclusions: We have shown that several potential urine
markers of MPS I, II and VI are detectable and quantifiable in
urine. These markers likely indicate impaired extracellular
matrix, endothelial function and lysosomal hypertrophy which
are key pathological feature of MPS. Importantly, we have
also been able to demonstrate a relationship between marker
concentrations and disease severity. All markers for MPS did
not show significantly raised levels in the clinically mild MPS
I and II groups which were in the control range. However,
three markers, (COMP, IGFBP7 and beta galactosidase) were
able to differentiate between the MPS II neurological and non-
neurological clinical phenotype. Further utility of these mark-
ers would be to determine severity of disease at initial diagno-
sis the patient’s ages in the severe disease cohorts start at 0.26-
1 yrs which indicates this may be possible however larger
numbers of samples taken at initial diagnosis need be assessed
to appropriately conclude this. The ability to discriminate dis-
ease severity indicates these markers have the potential to
determine the patient disease severity at initial diagnosis,
which is often in early life and at the stage where initiation of
treatment is crucial as well as reflect the effect of treatment on
the downstream pathology of the disease.
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